Cipla rose 1.09% to Rs 892.60 after the drug major entered into a licensing agreement with Lilly to expand access to Covid-19 treatment in India.Cipla announced it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company, USA for the manufacture and commercialization of the drug baricitinib for Covid-19 indication.
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Eli Lilly inks pacts for Baricitinib with Sun Pharma, Cipla, Lupin for COVID-19 treatment in India
yourstory.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yourstory.com Daily Mail and Mail on Sunday newspapers.
Cipla ties up with Eli Lilly to make, sell Baricitinib to treat COVID-19 patients in India
Baricitinib was issued a restricted emergency use approval by the health ministry s CDSCO for the use in combination with Remdesivir for treatment of Covid-19
BusinessToday.In | May 12, 2021 | Updated 11:33 IST
India is facing a huge shortage of essential medicines, equipment and medical oxygen as Covid-19 ravages the country
Cipla has entered into a licensing agreement with American pharma company Eli Lilly to expand access to COVID-19 treatment in India. Under the agreement, Cipla has got royalty-free, non-exclusive voluntary licensing rights for manufacturing and commercialisation of the drug Baricitinib for Covid-19.
URL copied
Cipla inks pact with Eli Lilly to produce, sell COVID-19 treatment drug
Drug major Cipla on Monday said it has inked a pact with US-based Eli Lilly and Company to manufacture and produce baricitinib in the country for the treatment of COVID-19. The Mumbai-based company said it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for baricitinib. Baricitinib has already received a restricted emergency use approval by the Central Drugs Standard Control Organisation (CDSCO), Ministry of Health, India, for use in combination with remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Drug major Cipla on Monday said it has inked a pact with US-based Eli Lilly and Company to manufacture and produce baricitinib in the country for the treatment of COVID-19. The Mumbai-based company said it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for baricitinib. Baricitinib has already received a restricted emergency use approval by the Central Drugs Standard Control Organisation (CDSCO), Ministry of Health, India, for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). This collaboration is a step further in the company s efforts to enhance access to critical treatments for patients affected by the pandemic, Cipla said in a statement.
vimarsana © 2020. All Rights Reserved.